Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $77.8 million.

  • vTv Therapeutics' Cash from Financing Activities rose 305891.19% to $77.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.8 million, marking a year-over-year increase of 4861.35%. This contributed to the annual value of $52.6 million for FY2024, which is 33850.13% up from last year.
  • Per vTv Therapeutics' latest filing, its Cash from Financing Activities stood at $77.8 million for Q3 2025, which was up 305891.19% from -$42000.0 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Cash from Financing Activities ranged from a high of $77.8 million in Q3 2025 and a low of -$282000.0 during Q4 2023
  • Over the past 5 years, vTv Therapeutics' median Cash from Financing Activities value was $5.0 million (recorded in 2022), while the average stood at $12.3 million.
  • Over the last 5 years, vTv Therapeutics' Cash from Financing Activities had its largest YoY gain of 471171.88% in 2023, and its largest YoY loss of 10769.02% in 2023.
  • vTv Therapeutics' Cash from Financing Activities (Quarter) stood at $266000.0 in 2021, then soared by 1278.57% to $3.7 million in 2022, then tumbled by 107.69% to -$282000.0 in 2023, then surged by 973.4% to $2.5 million in 2024, then soared by 3058.91% to $77.8 million in 2025.
  • Its last three reported values are $77.8 million in Q3 2025, -$42000.0 for Q2 2025, and $2.5 million during Q3 2024.